The study whether Sacubitril/Valsartan increase ultrafiltration and preserve residual kidney function in patients who are under peritoneral dialysis treatment.
Not Applicable
Recruiting
- Conditions
- Chronic kidney failure during peritoneal dialysis therapyChrnoic kidney failureD007676
- Registration Number
- JPRN-jRCT1031230413
- Lead Sponsor
- Yoshino Atsunori
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
1) Patients who obtained wrriten consent of participation in this research from patients or proxies.
2) Patinets who have hypertension or heart failure.
3) Patinets who underwent PET examination (PET, Weekly CCr, Weekly Kt/V, Daily urine volume mesurement) at least once.
Exclusion Criteria
1) Patients who take any angiotensin-converting-enzyme inhibitors within 36 hours of the start of the study.
2) Patients who have had side effects in the past with the drug or its ingredients (valsartan and/or neprilysin).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method